Literature DB >> 15142393

A chart review of cyproheptadine for stimulant-induced weight loss.

W Burleson Daviss1, John Scott.   

Abstract

Youths with attention deficit hyperactivity disorder often experience weight loss on stimulants, which may limit optimal dosing and compliance. Cyproheptadine has been shown in medical samples to stimulate weight gain. We conducted a retrospective chart review of 28 consecutive pediatric psychiatry outpatients prescribed cyproheptadine for weight loss or insomnia while on stimulants. Of these, 4 patients never took cyproheptadine consistently, and 3 discontinued it within the first 7 days due to intolerable side effects. Data were analyzed for 21 other patients (age range 4-15 years) who continued with 4-8 mg of cyproheptadine nightly (mean final dose = 4.9 mg/day) for at least 14 days (mean duration = 104.7 days). Most had lost weight on stimulant alone (mean weight loss was 2.1 kg, mean weight velocity was -19.3 g/day). All 21 gained weight taking concomitant cyproheptadine, with a mean gain of 2.2 kg (paired t = 6.87, p < 0.0001) and a mean weight velocity of 32.3 g/day. Eleven of 17 patients who had reported initial insomnia on stimulant alone noted significant improvements in sleep with cyproheptadine added. We conclude that concomitant cyproheptadine may be useful in youths with attention deficit hyperactivity disorder for stimulant-induced weight loss, pending future randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142393     DOI: 10.1089/104454604773840508

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  9 in total

1.  A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants.

Authors:  James G Waxmonsky; William E Pelham; Adriana Campa; Daniel A Waschbusch; Tan Li; Rebecca Marshall; Lysett Babocsai; Hugh Humphery; Elizabeth Gnagy; James Swanson; Tomasz Hanć; Negar Fallahazad; William E Pelham
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-08-29       Impact factor: 8.829

Review 2.  Managing the risks of ADHD treatments.

Authors:  Benjamin N Schneider; Michael Enenbach
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

3.  The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia.

Authors:  Marisa Couluris; Jennifer L R Mayer; David R Freyer; Eric Sandler; Ping Xu; Jeffrey P Krischer
Journal:  J Pediatr Hematol Oncol       Date:  2008-11       Impact factor: 1.289

Review 4.  Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.

Authors:  Jon Jureidini; Anne Tonkin; Elsa Jureidini
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

5.  Drug therapy of attention deficit hyperactivity disorder: current trends.

Authors:  Avinash De Sousa; Gurvinder Kalra
Journal:  Mens Sana Monogr       Date:  2012-01

6.  Beneficial effect of cyproheptadine on body mass index in undernourished children: a randomized controlled trial.

Authors:  Khadijehsadat Najib; Mozhgan Moghtaderi; Zohreh Karamizadeh; Ebrahim Fallahzadeh
Journal:  Iran J Pediatr       Date:  2014-12-12       Impact factor: 0.364

Review 7.  Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents.

Authors:  Raman Baweja; Daniel E Hale; James G Waxmonsky
Journal:  CNS Drugs       Date:  2021-07-23       Impact factor: 5.749

Review 8.  Cancer cachexia--pathophysiology and management.

Authors:  Hajime Suzuki; Akihiro Asakawa; Haruka Amitani; Norifumi Nakamura; Akio Inui
Journal:  J Gastroenterol       Date:  2013-03-20       Impact factor: 7.527

9.  Effects of Folic Acid on Appetite in Children with Attention Deficit Hyperactivity Disorder (ADHD) Treated with Methylphenidate: A Randomized Double-Blind Clinical Trial.

Authors:  Forough Riahi; Ashraf Tashakori; Ghazal Salehi Vanani
Journal:  Iran J Med Sci       Date:  2018-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.